Disc Medicine, Inc. (NASDAQ:IRON) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $122.70.

IRON has been the subject of several recent research reports. Morgan Stanley upped their target price on shares of Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a research report on Tuesday. Wedbush increased their target price on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday. Jefferies Financial Group reissued a “buy” rating and set a $149.00 price target on shares of Disc Medicine in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research note on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $120.00 target price on shares of Disc Medicine in a research note on Thursday, September 10th.

Key Stories Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Encouraging bitopertin Phase 3 results: Disc Medicine discussed topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP), supporting optimism around the drug’s potential in serious hematologic diseases. APOLLO Phase 3 results
• Positive Sentiment: Jefferies raised its price target to $149: The target increase reflects greater confidence in bitopertin following the Phase 3 update and provides a favorable valuation signal for IRON. Jefferies price target increase
• Positive Sentiment: $450 million financing improves financial flexibility: Disc Medicine priced an upsized offering of 6 million shares at $75 each, with an option for underwriters to purchase 900,000 additional shares. The proceeds should fund clinical development, research and potential commercialization of bitopertin, extending the company’s runway.
• Neutral Sentiment: Unusually high options volume points to elevated investor interest and potentially higher volatility, but does not provide a clear directional signal. Unusually high options volume
• Negative Sentiment: Equity dilution is a near-term headwind: Issuing 6 million new shares increases the share count and may pressure the stock around the $75 offering price, even though the capital strengthens the balance sheet. Disc Medicine public offering
• Negative Sentiment: Director selling adds an overhang: Director Kevin Bitterman sold 41,825 shares for approximately $3.35 million across October 19–21, substantially reducing his direct position. The sales were made under a pre-arranged Rule 10b5-1 plan, making them less indicative of current expectations but still adding potential supply. Kevin Bitterman SEC filing

Insider Buying and Selling

In other Disc Medicine news, Director Kevin Bitterman sold 25,519 shares of the stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $80.23, for a total value of $2,047,389.37. Following the completion of the sale, the director owned 12,991 shares in the company, valued at $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 173,046 shares of company stock worth $13,591,034. Corporate insiders own 3.76% of the company’s stock.

Hedge Funds Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its position in Disc Medicine by 842.4% during the third quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock worth $61,000 after buying an additional 834 shares in the last quarter. Pinnacle Associates Ltd. bought a new stake in shares of Disc Medicine during the 3rd quarter valued at $2,310,000. Assenagon Asset Management S.A. lifted its position in Disc Medicine by 191.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,119,458 shares of the company’s stock worth $73,280,000 after purchasing an additional 735,300 shares during the period. Opaleye Management Inc. lifted its position in Disc Medicine by 103.1% during the second quarter. Opaleye Management Inc. now owns 855,000 shares of the company’s stock worth $62,535,000 after purchasing an additional 434,000 shares during the period. Finally, Engineers Gate Manager LP lifted its position in Disc Medicine by 110.9% during the second quarter. Engineers Gate Manager LP now owns 19,552 shares of the company’s stock worth $1,430,000 after purchasing an additional 10,282 shares during the period. 83.70% of the stock is owned by institutional investors.

Disc Medicine Trading Down 1.3%

IRON opened at $75.03 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -11.40 and a beta of 0.93. The firm has a 50 day simple moving average of $71.34 and a 200 day simple moving average of $71.54. Disc Medicine has a fifty-two week low of $40.00 and a fifty-two week high of $99.50.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, sell-side analysts anticipate that Disc Medicine will post -6.61 earnings per share for the current year.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.